miR-1

rna

miR-1 is released from ischemic myocardium and dysregulated in MI; elevated levels indicate cardiomyocyte injury and arrhythmia risk.

Pathway placement

Cascade stepMyocardial injury (shared endpoint)

Confidencemedium

RationaleCardiac injury biomarker; dysregulated in AMI and ischemia-reperfusion; involved in arrhythmia and platelet activation.

Also acts inPlatelet activation

Druggability

Not assessed (no mapped human gene target).

Type I vs Type II discrimination

ScoresType-II-associated

R — rupture / Type-I

—

C — confounder / Type-II

A — assay feasibility

E — evidence strength

T1DI (composite)

Specificity differential (R−C)-51.7

Confounder panel (Type-II drivers)

1sepsis / systemic inflammationn/a

2anemia / acute blood lossn/a

3hypovolemia / dehydrationn/a

4tachyarrhythmiamag 2

5hypoxemia / respiratory failuren/a

6hypertensive emergencymag 2

7high-demand / peri-operative stressn/a

Coverage: 2/7 confounders with evidence

Tier: deep-scored (abstract-extracted) · 5 supporting references. See the discrimination table for all markers.

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.

Specimen

Whole blood or cell-free plasma

Collection tube

PAXgene/Tempus RNA tube · K2/K3-EDTA (lavender-top)

Method / principle

RT-qPCR (TaqMan) or small-RNA sequencing

Reagent / substrate

Target-specific primers/probe; reverse transcriptase (miRNA: stem-loop RT primer)

Platform

qPCR instrument / NGS

Turnaround · availability

Research / send-out · Research (few LDTs)